Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Chemotherapy in Bronchiolo-alveolar Carcinoma
NCT00384826Phase 2Completed
- Sponsor
- IFCT
- Start
- Sep 2006
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in bronchioloalveolar carcinoma (BAC) (2 arms), sponsored by IFCT. Primary endpoint: Disease Control Rate at 16 weeks. Started Sep 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
bronchioloalveolar carcinoma (BAC)
Beyond the preview
Go deeper on NCT00384826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384826.